CF
TRDA icon

Corebridge Financial’s Entrada Therapeutics TRDA Stock Holding History

Corebridge Financial’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,096
Closed -$109K – 2569
2025
Q1 		$109K Sell
12,096
-180
-1% -$2.24K ﹤0.01% 2388
2024
Q4 		$212K Sell
12,276
-927
-7% -$16.8K ﹤0.01% 2145
2024
Q3 		$211K Sell
13,203
-81
-0.6% -$1.28K ﹤0.01% 2203
2024
Q2 		$189K Buy
+13,284
New +$189K ﹤0.01% 2227

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Corebridge Financial's TRDA Position: Q2 2025 in Review

Corebridge Financial sold out of Entrada Therapeutics (TRDA) in Q2 2025, closing a stake of 12,096 shares — an estimated $109K sold.

Corebridge Financial first reported a position in TRDA in Q2 2024 and held it in 4 quarters. The position peaked at $212K in Q4 2024. 107 funds tracked by Wall St. Rank hold TRDA as of Q2 2025.

  • Corebridge Financial reported no remaining Entrada Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 12,096 Entrada Therapeutics shares in Q2 2025, an estimated $109K.
  • Corebridge Financial first reported a position in Entrada Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Entrada Therapeutics position peaked at $212K in Q4 2024.
  • 107 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.